Endeavor notches major mid-stage trial win, says IPF drug can reverse disease

Endeavor BioMedicines' IPF drug meets Phase 2b primary endpoint

Endeavor BioMedicines announced that taladegib met the primary endpoint in a Phase 2b study for idiopathic pulmonary fibrosis, with the company claiming the drug has potential to reverse disease course rather than just slow progression.